Fig. 7From: Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysisMeta-based influence analysis for comparisons of OS (a), total AEs (b) and grade 3–5 AEs (c)Back to article page